t
Futura Medical plc announced on 31 July 2023 its total issued share capital and voting rights. The company stated its total issued share capital as 300,712,293 Ordinary Shares. With no shares held in treasury, the total number of voting rights is also 300,712,293 for shareholders' use under FCA Disclosure and Transparency Rules.
| Date | 31 Jul 2023 |
| Time | 07:00:04 |
| Category | Capital structure |
| ID | 6174H |
31 July 2023
Futura Medical plc
("Futura" or the "Company")
Total Voting Rights
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, announces that for the purposes of the FCA's Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 300,712,293 Ordinary Shares.
Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is 300,712,293 and this figure may therefore be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
ENDS
Futura Medical plc
James Barder, Chief Executive Officer
Angela Hildreth, Finance Director and COO
Email: [email protected]
Tel: +44 (0) 1483 685 670
Nominated Adviser and Sole Broker:
Liberum
Phil Walker/ Richard Lindley/ Ben Cryer
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Eva Haas/ Hollie Vile/ Jonathan Edwards/ Zoe Bolt
Email: [email protected]
Tel: +44 (0) 203 882 9621